iRegene Therapeutics' Cell Therapy for Retinitis Pigmentosa Cleared for U.S. and China Clinical Trials

iRegene Therapeutics has received clearance from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its investigational cell therapy, NouvSight001. This allogeneic, off-the-shelf photoreceptor cell therapy is designed to treat retinitis pigmentosa (RP), a degenerative eye disease, and is not limited by a patient's specific genotype. The clearances mark a significant advancement in the global development of this novel cell replacement therapy.